A citation-based method for searching scientific literature

J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, S Peters, E Dansin, M Früh, M Pless, R Rosell, M Wislez, P Fournel, V Westeel, F Cappuzzo, A Cortot, D Moro-Sibilot, J Milia, O Gautschi. Ann Oncol 2016
Times Cited: 182







List of co-cited articles
885 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
405
56

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
196
54

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
M G Kris, D R Camidge, G Giaccone, T Hida, B T Li, J O'Connell, I Taylor, H Zhang, M E Arcila, Z Goldberg,[...]. Ann Oncol 2015
180
51

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
280
50

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang, C Rivard, G Gao, T L Ng, M M Tu,[...]. Ann Oncol 2019
93
40

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh S Ramalingam, Fadlo R Khuri. Cancer 2017
81
43

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, Juergen Wolf, Bartosz Wasąg, Wojciech Biernat, Stephen P Finn, Roswitha Kammler, Zoi Tsourti, Manuela Rabaglio,[...]. J Thorac Oncol 2019
55
60

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Bob T Li, Dara S Ross, Dara L Aisner, Jamie E Chaft, Meier Hsu, Severine L Kako, Mark G Kris, Marileila Varella-Garcia, Maria E Arcila. J Thorac Oncol 2016
134
32

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I Shapiro, Dejan Juric, David I Quinn, Victor Moreno, Bernard Doger,[...]. Nature 2018
349
30

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, C Barton, P Ghahramani, V Hirsh. Ann Oncol 2004
264
29

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
201
29

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada,[...]. J Thorac Oncol 2018
74
39

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
W Victoria Lai, Louisiane Lebas, Tristan A Barnes, Julie Milia, Ai Ni, Oliver Gautschi, Solange Peters, Roberto Ferrara, Andrew J Plodkowski, John Kavanagh,[...]. Eur J Cancer 2019
48
60

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
90
31

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
26

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
345
26

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Hisayuki Shigematsu, Takao Takahashi, Masaharu Nomura, Kuntal Majmudar, Makoto Suzuki, Huei Lee, Ignacio I Wistuba, Kwun M Fong, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. Cancer Res 2005
503
25


Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
24

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
J De Grève, E Teugels, C Geers, L Decoster, D Galdermans, J De Mey, H Everaert, I Umelo, P In't Veld, D Schallier. Lung Cancer 2012
203
24

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
412
23

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Solange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, Jin-Yuan Shih, Wei-Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih-Hsin Yang, Robert M Lorence,[...]. J Thorac Oncol 2018
47
48

Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'Meara, Raffaella Smith, Adrian Parker,[...]. Nature 2004
591
23

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang,[...]. J Clin Oncol 2020
47
46

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese Pisegna, Alissa Poteete, Huiying Sun,[...]. Cancer Cell 2019
65
32

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
20

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
260
20

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
20

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
19

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
19

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
186
19

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
91
20

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
18

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
227
18

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Jacques De Grève, Teresa Moran, Marie-Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean-Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey,[...]. Lung Cancer 2015
59
30

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Jody C Chuang, Henning Stehr, Ying Liang, Millie Das, Jane Huang, Maximilian Diehn, Heather A Wakelee, Joel W Neal. J Thorac Oncol 2017
58
29

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
84
20

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa, Valentina Pirazzoli, Maria E Arcila, Caroline A Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y Janjigian, Paula J Spitzler, Mary Ann Melnick,[...]. Cancer Discov 2012
496
16

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
168
16

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
16

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Yan Wang, Shijia Zhang, Fengying Wu, Jing Zhao, Xuefei Li, Chao Zhao, Shengxiang Ren, Caicun Zhou. BMC Cancer 2018
23
69

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
15

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
248
15

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
344
14

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
14

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
390
14

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
578
14

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
197
14

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
533
14

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.